Bender Robert & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$226K	Buy	+23,710	New	+$184K	0.05%	42
2025 Q4	–	Sell	-23,710	Closed	-$180K	–	41
2025 Q3	$180K	Hold	23,710	–	–	0.04%	45
2025 Q2	$212K	Buy	+23,710	New	+$221K	0.05%	44
2025 Q1	–	Sell	-23,710	Closed	-$178K	–	42
2024 Q4	$178K	Buy	+23,710	New	+$180K	0.04%	45
2024 Q1	–	Sell	-56,600	Closed	-$339K	–	44
2023 Q4	$339K	Hold	56,600	–	–	0.09%	40
2023 Q3	$401K	Sell	56,600 -12,000	-17%	-$86.2K	0.12%	39
2023 Q2	$483K	Hold	68,600	–	–	0.13%	39
2023 Q1	$572K	Buy	+68,600	New	+$660K	0.18%	41
2022 Q4	–	Sell	-68,600	Closed	-$864K	–	49
2022 Q3	$864K	Hold	68,600	–	–	0.33%	34
2022 Q2	$726K	Buy	+68,600	New	+$708K	0.28%	36